Innovating Works

EBOVAC3

Financiado
Bringing a prophylactic Ebola vaccine to licensure
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost pro... The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as: A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year. ver más
30/09/2024
51M€
Duración del proyecto: 75 meses Fecha Inicio: 2018-06-15
Fecha Fin: 2024-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 51M€
Líder del proyecto
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICIN... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5